Investor Presentaiton

PSA: Sotyktu Phase 2 responses provide confidence for Phase 3 Unmet need: Effective, tolerable, oral options with a novel mechanism to address both skin and joint involvement Phase 2 Primary Endpoint: ACR20 over time¹ POETYK-PSA-12 Phase 3 program ongoing data anticipated 2024/2025 Response rate, % 80 70 60 50 10 R320 40 • P < 0.001 62.7% Active disease; biologic DMARD-naïve ≥ 1 PSA-related hand and/or foot joint erosion on X-ray Week 16 Primary endpoint: ACR20 52.9% R Placebo deucravacitinib 6 mg QD 31.8% 1:1 LTE deucravacitinib 6 mg QD 0 1 2 4 8 12 16 Weeks Placebo deucravacitinib 6 mg QD deucravacitinib 12 mg QD All primary and key secondary endpoints were achieved in patients with active PsA Treatment was well-tolerate with a safety profile consistent with prior studies 1. Mease PJ et al. Ann Rheum Dis. 2022;81:815-822. 2. NCT04908202; 3. NCT04908189 Ill Bristol Myers Squibb™ POETYK-PSA-23 . Active disease; biologic DMARD-naive OR TNF inhibitor experienced Week 16 Primary endpoint: ACR20 deucravacitinib 6 mg QD R 3:3:1 Placebo deucravacitinib 6 mg QD apremilast 30 mg BID LTE Not for Product Promotional Use 153

View entire presentation